Biotech & Life Sciences Investor Relations
In this episode of The Investor Relations Podcast, Michael Loftus, Biotech Growth Architect and Family Office Strategist, shares his perspective on what makes investor relations effective in the fast-moving world of life sciences. Drawing from his experience at the intersection of biotech investing, clinical trials, and family office strategy, Michael explains how companies can strengthen relationships with investors and avoid common pitfalls.
The conversation explores why biotech companies must prioritize consistent communication, transparency, and brand awareness to stand out in a crowded field. Michael also highlights the importance of tailoring outreach to specialized investors instead of taking a broad “spray and pray” approach. For executives, IR officers, and capital markets professionals, this discussion provides actionable insights into building credibility, trust, and long-term partnerships within biotech and life sciences.
Connect with the Guest
- Company: https://www.poccap.com
- LinkedIn: https://www.linkedin.com/in/mikeloftusclinicaltrials/
- Podcast profile: View all of their episodes here
Connect with the Host
- Joshua Wilson LinkedIn: https://www.linkedin.com/in/joshuabrucewilson/
- The Investor Relations Podcast YouTube channel: https://www.youtube.com/@TheInvestorRelationsPodcast
#InvestorRelations #Biotech #LifeSciences #CapitalMarkets #FamilyOffice #ShareholderEngagement
Disclaimer: Joshua Wilson is a licensed Florida real estate broker and holds FINRA Series 79 and Series 63 licensure. The content of this podcast is for informational and educational purposes only and should not be considered legal, financial, or compliance advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners should consult their own legal counsel, compliance teams, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.
Let’s Connect on LinkedIn:
https://www.linkedin.com/in/joshuabrucewilson/
To Contact Us, Please Visit:
Joshua:
All right. So why don't you give us an overview of maybe some things people do really well in investor relations when working with biotech, and maybe some things that you might want to avoid.
Michael Loftus:
Sure. So a lot of investor relations firms reach out to me and to POC Capital to try to get us in front of different biotechs. And I like the companies that actually take the time to understand what we're working on and what we're needing. Sometimes companies will just spam me with a whole bunch of different verticals not specific to biotech, and I have to nicely tell them, “Hey, we're just really laser-focused in biotech.”
So that, from the corporate side talking to POC Capital, happens sometimes. And from the other side—from the biotech side—I think biotechs really need to focus on getting more information out there consistently. Consistently getting information out there so everybody can see what the company's up to and engage with the company, and find reasons to talk to them a little more. I think it’s really about more awareness and brand building by getting updates out to the internet and other places where people can see you and understand what you're working on.
Michael Loftus
Director
I am passionate about driving innovation and growth as a Biotech Growth Architect and Family Office Strategist, blending board-level leadership with hands-on expertise across Public Microcap Biotech, global CRO, pharmacology, and eClinical sectors. Throughout my career, I have thrived on scaling breakthrough ideas and accelerating clinical and eClinical commercialization, consistently delivering tangible value for organizations leading the charge in life sciences.
Renowned as a connector and APEX hunter, I eagerly embrace opportunities to forge strategic partnerships and navigate the dynamic, ever-evolving biotech landscape. My high emotional intelligence (EQ) empowers me to inspire diverse teams, foster genuine collaboration, and build lasting trust among stakeholders—ensuring we achieve outstanding results even in the most challenging environments.
Board-ready and energized by the future, I am deeply committed to advancing transformative solutions that shape the next era of biotech and healthcare. My approach unites visionary strategy with operational excellence, positioning organizations for sustainable growth and lasting impact.
On a personal note, I am happily married and the proud parent of four amazing kids—two 15-year-olds, a 10-year-old, and a 7-year-old—plus our beloved dog, Riley. During downtime, my family and I love to travel, whether we’re soaking up the sun at the beach or exploring the mountains. I’m also passionate about exercise, as it’s my favorite way to recharge and embrace each new day with energy and optimism.